Individual commitment to a group effort – that is what makes a team work, a company work, a society work, a civilization work.
– Vince Lombardi
Charles Hu, PhD, CEO
As Chief Executive Officer, Dr. Charles Hu acts as the interface between Incando Therapeutics and the public. He is also responsible for the company’s clinical strategy and key advisor relationships.
Charles received his PhD in translational tissue engineering from Johns Hopkins University and was most recently a regional Medical Affairs Lead at AstraZeneca where he oversaw the product launch cycles of several blockbuster drugs. He has extensive experience in clinically relevant translational studies, medical affairs, technology transfer, business development, and serves as an advisor to multiple angel investors.
James Robinson, JD, COO
JR is Incando’s Chief Operating Officer, focusing on all aspects of business development and operations. He has over 15 years of experience engaged in intellectual property matters in the life sciences, focusing in the areas of patent procurement and assertion, transactions, technology transfer, and strategic alliances.
Cheng-Wei Pei, CTO
Cheng brings over 15 years of industry experience developing medical devices, optical and electrochemical biosensors, high-volume consumer smartphone sensors, and high-performance analog semiconductors to Incando. His previous startup experience are in neurostimulation, continuous glucose monitoring, and wound therapy medical device companies. Cheng has a history of working in innovative technology, with 12 issued U.S. patents and several more pending.
Incando Therapeutics 